Why Iradimed Stock Soared Today
Key Points
For the 18th time in a row, the niche medical device maker set a new all-time high for quarterly revenue.
It also handily topped the consensus analyst estimate for adjusted net profit.
- 10 stocks we like better than Iradimed Corporation ›
The stock of advanced medical devices maker Iradimed (NASDAQ: IRMD) was the very picture of health on Tuesday. The company released its latest earnings report, which revealed that -- for the 18th quarter in a row -- it set a new all-time high revenue figure. Also, both the top and bottom lines rose at double-digit rates. Investors rewarded this by trading the stock up by nearly 10% that day.
Yet another peak
In its fourth quarter of 2025, Iradimed earned $22.7 million in revenue, a 17% improvement over the same period of 2024. Net income not in accordance with generally accepted accounting practices (GAAP) flew higher, rising 23% to just under $7 million ($0.54 per share).
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Image source: Getty Images.
With that bottom-line figure, Iradimed notched the latest in a series of beats on the consensus analyst estimate, which in this instance was $0.48 per share. The average pundit projection for revenue wasn't immediately available.
The company, which specialized in intravenous infusion pump systems and monitoring systems designed to work with magnetic resonance imaging (MRI) procedures, benefited from the rollout of a new product. This is the 3870 intravenous infusion pump, which the company began shipping during the quarter.
Iradimed also announced a dividend raise in its earnings release. The company's quarterly payout is to rise from $0.17 per share to $0.20, effective with the next distribution. This will take place on March 6 for investors of record as of Feb. 23.
More growth in store?
Iradimed also proffered guidance for the entirety of 2026. It's estimating that revenue will come in at $91 million to $96 million, filtering down into non-GAAP (adjusted) net income of $2.06 to $2.21. Both ranges sit comfortably above the $73 million in revenue and $1.66 per share adjusted net profit of 2024.
There are numerous value stocks hidden in the niche medical devices segment, and Iradimed occupies a strong one in MRI-compatible equipment. The company continues to march down a growth path, so I think it's stock is well worth considering as a buy
Should you buy stock in Iradimed Corporation right now?
Before you buy stock in Iradimed Corporation, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Iradimed Corporation wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $439,362!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,164,984!*
Now, it’s worth noting Stock Advisor’s total average return is 918% — a market-crushing outperformance compared to 196% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of February 10, 2026.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Iradimed. The Motley Fool has a disclosure policy.
Recommended Articles
